OMERS ADMINISTRATION Corp Has $9.24 Million Stock Position in Abbott Laboratories $ABT

OMERS ADMINISTRATION Corp increased its holdings in shares of Abbott Laboratories (NYSE:ABT) by 26.9% in the first quarter, HoldingsChannel reports. The firm owned 89,968 shares of the healthcare product maker’s stock after buying an additional 19,094 shares during the period. OMERS ADMINISTRATION Corp’s holdings in Abbott Laboratories were worth $9,237,000 as of its most recent filing with the SEC.

Several other institutional investors and hedge funds have also recently bought and sold shares of ABT. Freemont Management S.A. increased its position in Abbott Laboratories by 197.2% during the 4th quarter. Freemont Management S.A. now owns 10,700 shares of the healthcare product maker’s stock worth $1,341,000 after buying an additional 7,100 shares during the period. PFA Pension Forsikringsaktieselskab bought a new stake in shares of Abbott Laboratories in the fourth quarter valued at about $116,580,000. Thrivent Financial for Lutherans grew its stake in shares of Abbott Laboratories by 24.3% in the fourth quarter. Thrivent Financial for Lutherans now owns 246,586 shares of the healthcare product maker’s stock valued at $30,931,000 after acquiring an additional 48,286 shares in the last quarter. Mn Services Vermogensbeheer B.V. increased its position in Abbott Laboratories by 2.1% during the fourth quarter. Mn Services Vermogensbeheer B.V. now owns 671,743 shares of the healthcare product maker’s stock worth $84,163,000 after acquiring an additional 13,543 shares during the period. Finally, Aureus Asset Management LLC raised its stake in Abbott Laboratories by 25.0% in the 1st quarter. Aureus Asset Management LLC now owns 331,920 shares of the healthcare product maker’s stock worth $34,078,000 after purchasing an additional 66,422 shares in the last quarter. Institutional investors own 75.18% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of brokerages have issued reports on ABT. TD Cowen restated a “buy” rating and set a $115.00 target price on shares of Abbott Laboratories in a research report on Friday, July 17th. Piper Sandler reiterated an “overweight” rating and issued a $118.00 price target (up from $115.00) on shares of Abbott Laboratories in a research note on Friday, July 17th. The Goldman Sachs Group reduced their price target on Abbott Laboratories from $121.00 to $113.00 and set a “buy” rating on the stock in a research report on Wednesday, May 27th. Robert W. Baird assumed coverage on Abbott Laboratories in a research note on Wednesday, July 1st. They set an “outperform” rating and a $121.00 price objective on the stock. Finally, Bank of America cut their target price on Abbott Laboratories from $120.00 to $102.00 in a research report on Friday, June 12th. Three equities research analysts have rated the stock with a Strong Buy rating, nineteen have assigned a Buy rating, three have issued a Hold rating and one has given a Sell rating to the stock. According to MarketBeat, the stock has an average rating of “Moderate Buy” and a consensus target price of $118.61.

Abbott Laboratories Price Performance

Shares of NYSE:ABT opened at $103.13 on Monday. The firm has a 50 day moving average of $91.61 and a 200-day moving average of $101.16. Abbott Laboratories has a 12 month low of $81.97 and a 12 month high of $137.49. The company has a current ratio of 1.39, a quick ratio of 1.01 and a debt-to-equity ratio of 0.56. The stock has a market capitalization of $179.63 billion, a PE ratio of 33.38, a PEG ratio of 2.00 and a beta of 0.61.

Abbott Laboratories (NYSE:ABT) last posted its quarterly earnings results on Thursday, July 16th. The healthcare product maker reported $1.31 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.28 by $0.03. The business had revenue of $12.51 billion for the quarter, compared to analyst estimates of $12.52 billion. Abbott Laboratories had a net margin of 11.65% and a return on equity of 17.65%. The firm’s revenue for the quarter was up 13.0% on a year-over-year basis. During the same quarter last year, the business posted $1.26 EPS. Abbott Laboratories has set its Q3 2026 guidance at 1.380-1.46 EPS and its FY 2026 guidance at 5.450-5.60 EPS. On average, equities research analysts predict that Abbott Laboratories will post 5.52 EPS for the current fiscal year.

Abbott Laboratories Dividend Announcement

The company also recently declared a quarterly dividend, which will be paid on Monday, August 17th. Stockholders of record on Wednesday, July 15th will be paid a dividend of $0.63 per share. This represents a $2.52 dividend on an annualized basis and a dividend yield of 2.4%. The ex-dividend date of this dividend is Wednesday, July 15th. Abbott Laboratories’s dividend payout ratio (DPR) is presently 81.55%.

Abbott Laboratories Company Profile

Abbott Laboratories is a global healthcare company headquartered in Abbott Park, Illinois, that develops, manufactures and markets a broad portfolio of medical products and services. Founded in 1888, Abbott operates through multiple business areas that focus on diagnostics, medical devices, nutritionals and established pharmaceuticals. The company supplies hospitals, clinics, laboratories, retailers and direct-to-consumer channels with products intended to diagnose, treat and manage a wide range of health conditions.

In diagnostics, Abbott provides laboratory and point-of-care testing platforms and assays used to detect infectious diseases, chronic conditions and biomarkers; its Alinity family of instruments and rapid-test solutions are examples of this capability.